Pacira announces 104-week safety, efficay data for PCRX-201
BioSciences announced new data demonstrating its gene therapy for osteoarthritis candidate, PCRX-201, provided sustained ...
Business Wire18h
Global Healthy Living Foundation Brings Innovative and Patient-Centered Polymyalgia Rheumatica, Psoriatic, and Rheumatoid Arthritis Research to ACR Conv…
Global Healthy Living Foundation has 12 posters and Polymyalygia Rheumataca, Psoriasis and RA Research at American College of ...
Pacira Announces 104-Week Safety and Efficacy Data Following Local Administration of PCRX-201 for Moderate to Severe Osteoarthritis of the Knee
Participants were broken into two cohorts. The first cohort received one of three doses of PCRX-201. The second cohort received concurrent pretreatment with an intraarticular corticosteroid ...
Phase 3 study finds inebilizumab effective for immunoglobulin G4–related disease
An international, phase 3 clinical trial led by investigators at Mass General Brigham could improve the treatment of a rare disease that can cause debilitating symptoms.
Merck Spends Up To $3.3 Billion In An Insurance Policy Against Summit Therapeutics
Merck is playing defense against Summit Therapeutics with a $3.3 billion licensing deal announced Thursday for a cancer drug.
Eight conditions weight-loss jabs might be beneficial for
Knee cartilage is not designed for high stress loads. People who are overweight or obese are at a higher risk of developing osteoarthritis because of the extra stress on their knee joints, with many ...
Local physician weighs in on Diabetes
COLUMBUS, Ga. (WRBL) — 537 million adults worldwide live with the autoimmune disease Diabetes. Today is World Diabetes Day ...